Chiesi Group entered an exclusive collaboration and license with Arbor Biotechnologies to develop and commercialize Arbor’s ABO-101, a liver-directed gene editing candidate for primary hyperoxaluria type 1 (PH1), and to access Arbor’s broader editing platform for additional liver targets. The deal could generate more than $2.1 billion for Arbor and covers development of ABO-101 through global commercialization. ABO-101 uses lipid nanoparticles to deliver a Cas12i2-based editing system targeting HAO1 to reduce oxalate production in PH1 patients. The agreement marks Chiesi’s first major move into gene editing and accelerates Arbor’s clinical program, currently in a Phase I/II trial. The partnership highlights Big Pharma’s willingness to outsource cutting-edge editing modalities to specialist developers to build rare-disease pipelines.